Skip to main content
Top
Published in: Supportive Care in Cancer 4/2006

01-04-2006 | Original Article

EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care units

Authors: Sang Min Park, Myung Hee Park, Joo Hee Won, Kyoung Ok Lee, Wha Sook Choe, Dae Seog Heo, Si-Young Kim, Kyung Sik Lee, Young Ho Yun

Published in: Supportive Care in Cancer | Issue 4/2006

Login to get access

Abstract

Goals of work

Although the EuroQol (EQ-5D) is widely used for economic evaluation, it remains unclear whether it can be combined with medical data to predict survival in patients with terminal cancer.

Patients and methods

We carried out this prospective study on 142 terminal cancer patients in four hospice-palliative care units. Association was sought between survival time and a range of variables such as cancer site, performance, previous treatment, age, sex, pain, and EuroQol. The EQ-5D was transformed into the corresponding EQ-5D utility. For univariate analysis, we estimated differences in survival with the Gehan generalized Wilcoxon test. For those variables that were significant, we performed multivariate analysis using the Cox proportional hazard model.

Main results

Univariate analysis showed that sex, age, performance, previous use of chemotherapy, and the EQ-5D utility provided statistically significant prognostic survival information. The median survival time was 13.0 days for the group with an EQ-5D utility score lower than −0.5 and 21.0 days for the group with an EQ-5D utility score above −0.5. In multivariate analysis with the Cox proportional hazard model, an EQ-5D utility score ≤0.5 (RR 1.57, 95% confidence interval 1.06–2.33) was an independent negative predictor of survival.

Conclusions

The EQ-5D quality-of-life assessment tool might be useful for predicting survival time for terminal cancer patients.
Literature
1.
go back to reference Yun YH, Heo DS, Heo BY, Yoo TW, Bae JM, Ahn SH (2001) Development of terminal cancer prognostic score as an index in terminally ill cancer patients. Oncol Rep 8:795–800PubMed Yun YH, Heo DS, Heo BY, Yoo TW, Bae JM, Ahn SH (2001) Development of terminal cancer prognostic score as an index in terminally ill cancer patients. Oncol Rep 8:795–800PubMed
2.
go back to reference Coates A, Gebski V, Signorini D et al (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 10:1833–1838PubMed Coates A, Gebski V, Signorini D et al (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 10:1833–1838PubMed
3.
go back to reference Coates AS, Hurny C, Peterson HF et al (2000) Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol 18:3768–3774PubMed Coates AS, Hurny C, Peterson HF et al (2000) Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol 18:3768–3774PubMed
4.
go back to reference Blazeby JM, Brookes ST, Alderson D (2001) The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49:227–230PubMedCrossRef Blazeby JM, Brookes ST, Alderson D (2001) The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49:227–230PubMedCrossRef
5.
go back to reference Earlam S, Glover C, Fordy C et al (1996) Relation between tumor size, quality of life and survival in patients with colorectal liver metastases. J Clin Oncol 14:171–175PubMed Earlam S, Glover C, Fordy C et al (1996) Relation between tumor size, quality of life and survival in patients with colorectal liver metastases. J Clin Oncol 14:171–175PubMed
6.
go back to reference Montazeri A, Milroy R, Hole D et al (2001) Quality of life in lung cancer patients: an important prognostic factor. Lung Cancer 31:233–240PubMedCrossRef Montazeri A, Milroy R, Hole D et al (2001) Quality of life in lung cancer patients: an important prognostic factor. Lung Cancer 31:233–240PubMedCrossRef
7.
go back to reference Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M (2004) Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer 101:1090–1098PubMedCrossRef Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M (2004) Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer 101:1090–1098PubMedCrossRef
8.
go back to reference Tamburini M, Brunelli C, Rosso S, Ventafridda V (1996) Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 11:32–41PubMedCrossRef Tamburini M, Brunelli C, Rosso S, Ventafridda V (1996) Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 11:32–41PubMedCrossRef
9.
go back to reference Kopec JA, Willison KD (2003) A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 56:317–325PubMedCrossRef Kopec JA, Willison KD (2003) A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 56:317–325PubMedCrossRef
10.
go back to reference van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, Leer JW (2003) Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 95:222–229PubMedCrossRef van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, Leer JW (2003) Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 95:222–229PubMedCrossRef
13.
go back to reference Yun YH, Mendoza TR, Heo DS, Yoo T, Heo BY, Park HA, Shin HC, Wang XS, Cleeland CS (2004) Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. Oncology 66:439–444PubMedCrossRef Yun YH, Mendoza TR, Heo DS, Yoo T, Heo BY, Park HA, Shin HC, Wang XS, Cleeland CS (2004) Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. Oncology 66:439–444PubMedCrossRef
14.
go back to reference Glare PA, Eychmueller S, McMahon P (2004) Diagnostic accuracy of the palliative prognostic score in hospitalized patients with advanced cancer. J Clin Oncol 22:4823–4828. Erratum in: J Clin Oncol. 2005;23:248PubMedCrossRef Glare PA, Eychmueller S, McMahon P (2004) Diagnostic accuracy of the palliative prognostic score in hospitalized patients with advanced cancer. J Clin Oncol 22:4823–4828. Erratum in: J Clin Oncol. 2005;23:248PubMedCrossRef
15.
go back to reference Maltoni M, Pirovano M, Scarpi E, Marinari M, Indelli M, Arnoldi E, Gallucci M, Frontini L, Piva L, Amadori D (1995) Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 75:2613–2622PubMedCrossRef Maltoni M, Pirovano M, Scarpi E, Marinari M, Indelli M, Arnoldi E, Gallucci M, Frontini L, Piva L, Amadori D (1995) Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 75:2613–2622PubMedCrossRef
Metadata
Title
EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care units
Authors
Sang Min Park
Myung Hee Park
Joo Hee Won
Kyoung Ok Lee
Wha Sook Choe
Dae Seog Heo
Si-Young Kim
Kyung Sik Lee
Young Ho Yun
Publication date
01-04-2006
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 4/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0889-1

Other articles of this Issue 4/2006

Supportive Care in Cancer 4/2006 Go to the issue

Forthcoming Meetings

Forthcoming Meetings

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine